#United States #Austin #The Braff Group #Community Clinical Research #PhaseWell Research

Major Partnership in Clinical Research

The Braff Group has recently shared exciting news concerning its client, Community Clinical Research (CCR) based in Austin, Texas. CCR has now formed a strategic alliance with PhaseWell Research, a leading multisite clinical research organization. This partnership promises to significantly enhance access to clinical trials for communities while paving the way for groundbreaking advancements in medicine.

About Community Clinical Research

CCR has established a strong reputation as one of the most proficient clinical sites for inpatient-capable Central Nervous System (CNS) research in the United States. By collaborating with PhaseWell, CCR aims to improve connections between communities and essential clinical trials. Their commitment to integrating patients into research initiatives will not only foster hope but also help shape the future of medical treatments.

Community Clinical Research prides itself on its deep-rooted connection to the patient community in Austin. This is a result of lasting partnerships with healthcare providers, advocacy groups, group homes, and various clinical institutions throughout the region. The CCR clinical team, led by Dr. Brown, along with Principal Investigator Dr. Samuel Collier, Sub-Investigator Reid Luedecke, and PMHNP-BC Mark Embry, brings a wealth of expertise in both inpatient and outpatient CNS research methodologies. Their approach ensures that research studies are tailored to meet the specific needs and acuity levels of their participant population.

Enhancing Patient Access Through Partnership

The structure of this newly formed partnership is progressively aligned with PhaseWell's long-term objective of maximizing patient participation in clinical trials. PhaseWell Research is notable for facilitating innovative research opportunities, supported by its robust network of trusted research sites and community practices across the nation.

A pivotal aspect of this partnership is the integration of Community Clinical Research into PhaseWell's umbrella of neuropsychiatric research capabilities. This will include establishing a 20-bed psychiatric research unit that is purpose-built and staffed around the clock. The new unit will allow for complex CNS studies that necessitate intensive monitoring of participants. Furthermore, CCR's proprietary database, which spans 25 years and contains more than 1,200 past participants, combined with a referral network from over 150 community organizations, positions them as a preferred research provider for major Clinical Research Organizations (CROs). CCR's consistent ability to meet 100% target enrollment on nearly all protocols further underscores its reputation as a leader in clinical research initiatives.

The Future of Clinical Trials

With mental health issues on the rise and the need for innovative treatment approaches growing, the timing of this partnership could not be more critical. Both organizations aim to leverage their combined resources, patient networks, and clinical experience to initiate studies that address some of the pressing challenges in CNS research today. By collectively advancing patient access to clinical trials, they hope to make significant contributions to the development of new therapies and medical interventions.

About The Braff Group

Founded in 1998, The Braff Group is recognized as a leading advisory firm in healthcare mergers and acquisitions. Their specialization in behavioral health and related sectors has allowed them to facilitate nearly 400 transactions, ranking them among the top five firms in their industry. As exclusive financial advisors to Community Clinical Research, The Braff Group will continue to play a crucial role in promoting their progressive strategies in clinical research.

For more information on their services, visit The Braff Group’s website and connect with them on LinkedIn.

In conclusion, the partnership between Community Clinical Research and PhaseWell Research is set to transform the landscape of clinical research, making strides that could ultimately lead to life-changing medical breakthroughs for those in need.